LIM
TXG icon

Lancaster Investment Management’s 10x Genomics TXG Stock Holding History

Lancaster Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-621,779
Closed -$7.27M – 9
2025
Q3 		$7.27M Buy
+621,779
New +$8.11M 3.12% 7

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lancaster Investment Management's TXG Position: Q4 2025 in Review

Lancaster Investment Management sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 621,779 shares — an estimated $7.27M sold.

Lancaster Investment Management first reported a position in TXG in Q3 2025 and held it in 1 quarter. The position peaked at $7.27M in Q3 2025. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Lancaster Investment Management reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Lancaster Investment Management sold 621,779 10x Genomics shares in Q4 2025, an estimated $7.27M.
  • Lancaster Investment Management first reported a position in 10x Genomics in Q3 2025 and held it in 1 quarter.
  • Lancaster Investment Management's 10x Genomics position peaked at $7.27M in Q3 2025.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Lancaster Investment Management's 13F filing for Q4 2025, filed 12 Jan 2026.